Mochida Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4534.T

Mochida Pharmaceutical Co., Ltd. Dividends Paid for the year ending March 31, 2024: USD -19.07 M

Mochida Pharmaceutical Co., Ltd. Dividends Paid is USD -19.07 M for the year ending March 31, 2024, a 24.85% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.

Mochida Pharmaceutical Co., Ltd. Dividends Paid for the year ending March 31, 2023 was USD -25.38 M, a 10.32% change year over year.
Mochida Pharmaceutical Co., Ltd. Dividends Paid for the year ending March 31, 2022 was USD -28.30 M, a -1.00% change year over year.
Mochida Pharmaceutical Co., Ltd. Dividends Paid for the year ending March 31, 2021 was USD -28.02 M, a 9.73% change year over year.
Mochida Pharmaceutical Co., Ltd. Dividends Paid for the year ending March 31, 2020 was USD -31.04 M, a 2.37% change year over year.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

Tokyo Stock Exchange: 4534.T

Mochida Pharmaceutical Co., Ltd.

CEO	Mr. Naoyuki Mochida
IPO Date	Jan. 1, 2001
Location	Japan
Headquarters	1-1, Ichigaya-Honmura cho
Employees	1,522
Sector	Healthcare
Industries Biotechnology Cosmetics Personal Care Pharmaceuticals Plastics

Description

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

Key trends

Past 5 years